Erlend B Smeland
Overview
Explore the profile of Erlend B Smeland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
7486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bai B, Wise J, Vodak D, Nakken S, Sharma A, Blaker Y, et al.
Blood Cancer J
. 2024 Aug;
14(1):147.
PMID: 39191762
Follicular lymphoma (FL) is the most common indolent type of B-cell non-Hodgkin lymphoma. Advances in treatment have improved overall survival, but early relapse or transformation to aggressive disease is associated...
2.
Spasevska I, Sharma A, Steen C, Josefsson S, Blaker Y, Kolstad A, et al.
Blood Adv
. 2023 Sep;
7(23):7216-7230.
PMID: 37695745
Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest...
3.
Casey N, Klee C, Fane A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, et al.
J Biol Chem
. 2023 Jun;
299(7):104883.
PMID: 37269947
Chimeric antigen receptor (CAR) T-cell therapy has had considerable success in the treatment of B-cell malignancies. Targeting the B-lineage marker CD19 has brought great advances to the treatment of acute...
4.
Isaksen K, Galleberg R, Mastroianni M, Rinde M, Rusten L, Barzenje D, et al.
Haematologica
. 2023 Mar;
108(9):2454-2466.
PMID: 36861406
The International prognostic Index (IPI) is the most widely used clinical prediction model for diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but...
5.
Huse K, Bai B, Hilden V, Bollum L, Vatsveen T, Munthe L, et al.
J Immunol
. 2022 Nov;
209(10):2042-2053.
PMID: 36426942
The BCR consists of surface-bound Ig and a heterodimeric signaling unit comprised of CD79A and CD79B. Upon cognate Ag recognition, the receptor initiates important signals for B cell development and...
6.
Isaksen K, Beiske K, Smeland E, Jorgensen J, Brodtkorb M, Myklebust J, et al.
EJHaem
. 2022 Jul;
2(1):104-108.
PMID: 35846101
No abstract available.
7.
Isaksen K, Mastroianni M, Rinde M, Rusten L, Barzenje D, Ramslien L, et al.
Blood Adv
. 2021 Sep;
5(22):4771-4782.
PMID: 34543384
Patients with diffuse large B-cell lymphoma (DLBCL) have a median age of 70 years. Yet, empirical knowledge about the treatment of older patients is limited because they are frequently excluded...
8.
Ramis-Zaldivar J, Gonzalez-Farre B, Nicolae A, Pack S, Clot G, Nadeu F, et al.
Haematologica
. 2021 May;
106(10):2682-2693.
PMID: 33951889
Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma with an immunoblastic/large-cell morphology and terminal B-cell differentiation. The differential diagnosis from Burkitt lymphoma, plasma cell myeloma and some variants of diffuse...
9.
Oksvold M, Berglund U, Gad H, Bai B, Stokke T, Rein I, et al.
Sci Rep
. 2021 Mar;
11(1):6317.
PMID: 33737576
Chemo-immunotherapy has improved survival in B-cell lymphoma patients, but refractory/relapsed diseases still represent a major challenge, urging for development of new therapeutics. Karonudib (TH1579) was developed to inhibit MTH1, an...
10.
Koksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland E, Myklebust J, et al.
J Biol Chem
. 2020 Nov;
296:100116.
PMID: 33234592
CAR T cells targeting the B lymphocyte antigen CD19 have led to remarkable clinical results in B cell leukemia and lymphoma but eliminate all B lineage cells, leading to increased...